Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Breaking down the new standards for cancer care proposed by NHS... March 11, 2022 FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... July 12, 2021 FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for... July 1, 2022 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Load more HOT NEWS Emma Stone Motivated to Help Others After Her Mother Was Diagnosed... Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... Researchers Find a Way to Prevent Cancer Cells from Taking in... Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell...
